Serum Institute Seeks Inclusion of Covovax on CoWIN as Heterologous Booster Dose for Adults

0
36
Serum Institute Seeks Inclusion of Covovax on CoWIN as Heterologous Booster Dose for Adults


Covovax is manufactured via know-how switch from Novavax. (Image: Twitter/@adarpoonawalla)

Last month, COVID-19 Working Group headed by Dr N Ok Arora had additionally really helpful to the well being ministry inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults who’ve been vaccinated with two doses of both Covishield or Covaxin

Amid rising coronavirus circumstances, the Serum Institute of India has written a letter to the Union well being ministry in search of the inclusion of its COVID-19 vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources mentioned on Monday.

The letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) on March 27, they mentioned.

Last month, COVID-19 Working Group headed by Dr N Ok Arora had additionally really helpful to the well being ministry inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults who’ve been vaccinated with two doses of both Covishield or Covaxin.

The Drugs Controller General of India (DCGI) had on January 16 accepted the market authorisation for Covovax for those that have been administered two doses of both Covishield or Covaxin. Also, Covovax has been accepted by the World Health Organisation (WHO) and the US Food and Drug Administration (USFDA).

The DCGI had accepted Covovax for restricted use in emergency conditions in adults on December 28, 2021, within the 12-17 age group on March 9, 2022, and within the 7-11 age group on June 28, 2022, topic to sure circumstances.

Covovax is manufactured via know-how switch from US-based vaccine maker Novavax. It has been accepted by the European Medicines Agency for conditional advertising authorisation. It was granted emergency-use itemizing by WHO on December 17, 2021.

In August 2020, Novavax Inc. had introduced a licence settlement with the SII for the event and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate in India, and low and middle-income international locations.

Read all of the Latest India News right here

(This story has not been edited by News18 employees and is printed from a syndicated information company feed)



Source hyperlink